The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial).
2006 Jun
Journal Article
Authors:
Altmaier, E.M.;
Ewell, M.;
McQuellon, R.;
Geller, N.;
Carter, S.L.;
Henslee-Downey, J.;
Davies, S.;
Papadopoulos, E.;
Yanovich, S.;
Gingrich, R.
Secondary:
Biol Blood Marrow Transplant
Volume:
12
Pagination:
648-55
Issue:
6
PMID:
16737938
DOI:
10.1016/j.bbmt.2006.01.003
Keywords:
Adult; Bone Marrow Transplantation; Follow-Up Studies; Health Status; Humans; Immunosuppressive Agents; Interviews as Topic; Lymphocyte Depletion; quality of life; T-Lymphocytes; Time Factors; Tissue Donors
Abstract:
The primary objective of this study was to compare health-related quality of life (HRQL) in adult patients undergoing either ex vivo T cell-depleted bone marrow transplantation or conventional marrow transplantation. Data on patients' HRQL were gathered as part of a multicenter randomized trial comparing the effect of ex vivo T-cell depletion versus methotrexate and cyclosporine immunosuppression on disease-free survival. HRQL assessments were conducted at baseline, day +100, 6 months, 1 year, and 3 years. There were no treatment arm differences 1 year after transplantation on the Functional Assessment of Cancer Therapy, Bone Marrow Transplantation, the Medical Outcomes Study Short-Form 36, and the Centers for Epidemiological Studies of Depression. The lack of treatment differences was robust across types of data analyses that took baseline functioning into account and that recognized the sensitivity of outcome measures to assumptions concerning missing data. The trajectory of recovery revealed an initial decrease in function and then a recovery to pretreatment levels that were similar for both treatment arms. Furthermore, the patients in both treatment groups returned to a functional level that approximated general US population norms. Even though the incidence of acute graft-versus-host disease was slightly higher in the conventional treatment arm, T-cell depletion did not differentially affect HRQL at 1 year after transplantation.
